LRRK2-IN-1

LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

Product Specifications

CAS Number

[1234480-84-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; LRRK2

Type

Reference compound

Related Pathways

Apoptosis; Autophagy

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/LRRK2-IN-1.html

Purity

99.42

Solubility

DMSO : 30 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(OC)=C(NC2=NC=C3C(N(C4=C(C(N3C)=O)C=CC=C4)C)=N2)C=C1)N5CCC(CC5)N6CCN(CC6)C

Molecular Formula

C31H38N8O3

Molecular Weight

570.69

Precautions

H315, H319, H320

References & Citations

[1]Hermanson SB, et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation.PLoS One. 2012;7 (8) :e43580. Epub 2012 Aug 28.|[2]Deng, Xianming., et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology (2011), 7 (4), 203-205.|[3]Koshibu K, et al. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Pharmacology. 2015;96 (5-6) :240-7.|[4]Weygant N, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 6;13:103.